Reference pricing for pharmaceuticals: is the Australia–United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?

@article{Faunce2007ReferencePF,
  title={Reference pricing for pharmaceuticals: is the Australia–United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?},
  author={T. Faunce},
  journal={Medical Journal of Australia},
  year={2007},
  volume={187}
}
  • T. Faunce
  • Published 2007
  • Business, Medicine
  • Medical Journal of Australia
Amendments to the National Health Act 1953 (Cwlth) were legislated by the Australian federal government in 2007 with minimal public debate. The National Health Amendment (Pharmaceutical Benefits Scheme) Act 2007 includes several changes that will limit reference pricing under the Australian Pharmaceutical Benefits Scheme (PBS). Here, I argue that these amendments were influenced by the Australia–United States Free Trade Agreement (AUSFTA) particularly the Medicines Working Group established… Expand
Impact of the Australia—US Free Trade Agreement on Australian Medicines Regulation and Prices
The Australia—United States Free Trade Agreement (AUSFTA) came into force on 1 January 2005. Before and subsequently to the AUSFTA being concluded, controversy surrounded the debate over its impactExpand
How the Australia-US free trade agreement compromised the pharmaceutical benefits scheme
Australia’s Pharmaceutical Benefits Scheme (PBS) has unquestioned democratic legitimacy as a piece of public health policy. The PBS was approved by a majority of people in a majority of States in theExpand
The PBS in a globalised world: free trade and reference pricing.
  • A. Searles
  • Economics, Medicine
  • Australian health review : a publication of the Australian Hospital Association
  • 2009
TLDR
This article argues that recent reforms to the PBS partially delivered on an issue that the US has compelled its trade negotiators to ensure since 2002: the elimination of reference pricing. Expand
Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
TLDR
While pharmaceutical companies claim that Australia's pricing and reimbursement policies suppress drug prices and reduce profits, national policy audits indicate these claims are misguided. Expand
The Trans‐Pacific Partnership Agreement: challenges for Australian health and medicine policies
TLDR
Concern is that proposed TPPA multilateral investor–state dispute settlement procedures would allow US corporations to obtain damages against Australian governments through international arbitral proceedings if their investments are impeded by Australian public health and environment protection legislation. Expand
Bilateral trade agreements as drivers of national and transnational benefit from health technology policy: implications of recent US deals for Australian negotiations with China and India
This article compares controversial health technology provisions in two important United States free trade agreements with developed nations: Australia and with South Korea. It examines theExpand
What is Fair? Choice, Fairness, and Transparency in Access to Prescription Medicines in the United States and Australia
TLDR
This article examines the sharply contrasting prescription drug coverage and payment policies found in Australia and the U.S. – strong political allies and international trading partners – and describes how key U.s. interests have sought, through an aggressive trade agenda, to expand markets for U. S. goods and services, even when market expansions clash with other nations’ contrasting emphasis on social equity and fairness. Expand
Drug Price Reforms: The New F1–F2 Bifurcation
TLDR
The changes may allow PBS and patient savings through lower priced generics, but their impact on the price of patented medicines is uncertain in the authors' view. Expand
Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
  • J. Karnon, L. Edney, M. Sorich
  • Economics, Medicine
  • Australian health review : a publication of the Australian Hospital Association
  • 2017
TLDR
The effects of the non-maintenance of equivalent prices when the comparators of pharmaceuticals listed on the Pharmaceutical Benefits Schedule on a cost-minimisation basis come off-patent and are subject to statutory price reductions are illustrated. Expand
Effects of Reference Pricing in Pharmaceutical Markets
TLDR
A systematic and updated survey of original scientific studies on the effect of the introduction of reference pricing (RP) policies in Organisation for Economic Co-operation and Development (OECD) countries found that both therapeutic RP (TRP) and GRP have been associated with significant and consistent savings in the first years of application. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 30 REFERENCES
Will the Australia–United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme?
TLDR
Concerns are raised that the many concerned health and consumer organisations who have asked the Senate either not to pass the enabling legislation, or to delay its passage until a fairer deal in terms of public health can be obtained. Expand
Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy
TLDR
To the extent that the AUSFTA medicines provisions may represent animportant precedent in a global strategy by industry on cost-effectiveness evaluation of pharmaceuticals, the study will be of great interest to policy makers in other jurisdictions. Expand
'Linkage' pharmaceutical evergreening in Canada and Australia
TLDR
The regulatory lessons to be learnt from Canada and Australia's shared experience in terms of minimizing potential adverse impacts of so-called 'linkage evergreening' provisions on drug costs and thereby potentially on citizen's access to affordable, essential medicines are explored. Expand
Reform of drug regulation--beyond an independent drug-safety board.
TLDR
A new federal authority for drug regulation is proposed, to be made up of three independent centers: a Center for New Drug Approval, a Centre for Post-marketing Studies, and a Center For Drug Information. Expand
Chairman of Medicines Australia)
  • National Press Club speech 2005. Pharma in Focus 2005; 8 Aug. http://www.pharmainfocus.com.au/
  • 2007
Independent Review (PBS
  • Independent Review (PBS
  • 2007
PBS cost recovery consultations are happening
  • PBS cost recovery consultations are happening
  • 2007
Proposed United States–Korea FTA texts. Chapter Five. Pharmaceuticals and medical devices
  • Proposed United States–Korea FTA texts. Chapter Five. Pharmaceuticals and medical devices
  • 2007
AUSFTA – Medicines Working Group – 2007 meeting statement Proposed United States – Korea FTA texts . Chapter Five . Pharmaceuticals and medical devices
  • The Australian
  • 2006
Australia–US Medicines Working Group holds first meeting
  • Australia–US Medicines Working Group holds first meeting
  • 2006
...
1
2
3
...